Recombinant endolysins as potential therapeutics against antibiotic-resistant staphylococcus aureus: Current status of research and novel delivery strategies

Haddad Kashani, H. and Schmelcher, M. and Sabzalipoor, H. and Seyed Hosseini, E. and Moniri, R. (2018) Recombinant endolysins as potential therapeutics against antibiotic-resistant staphylococcus aureus: Current status of research and novel delivery strategies. Clinical Microbiology Reviews, 31 (1).

[img] Text
e00071-17.full.pdf

Download (1MB)
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....
DOI: UNSPECIFIED

Abstract

Staphylococcus aureus is one of the most common pathogens of humans and animals, where it frequently colonizes skin and mucosal membranes. It is of major clinical importance as a nosocomial pathogen and causative agent of a wide array of diseases. Multidrug-resistant strains have become increasingly prevalent and represent a leading cause of morbidity and mortality. For this reason, novel strategies to combat multidrug-resistant pathogens are urgently needed. Bacteriophage-derived enzymes, socalled endolysins, and other peptidoglycan hydrolases with the ability to disrupt cell walls represent possible alternatives to conventional antibiotics. These lytic enzymes confer a high degree of host specificity and could potentially replace or be utilized in combination with antibiotics, with the aim to specifically treat infections caused by Gram-positive drug-resistant bacterial pathogens such as methicillin-resistant S. aureus. LysK is one of the best-characterized endolysins with activity against multiple staphylococcal species. Various approaches to further enhance the antibacterial efficacy and applicability of endolysins have been demonstrated. These approaches include the construction of recombinant endolysin derivatives and the development of novel delivery strategies for various applications, such as the production of endolysins in lactic acid bacteria and their conjugation to nanoparticles. These novel strategies are a major focus of this review. © 2017 American Society for Microbiology. All Rights Reserved.

Item Type: Article
Additional Information: cited By 17
Uncontrolled Keywords: aminoglycoside; amoxicillin; ampicillin; beta lactam; carbapenem; carbenicillin; cephalosporin; cilastatin plus imipenem; daptomycin; endolysin LysK; glycopeptide; linezolid; macrolide; monobactam derivative; oxacillin; penicillin G; penicillin V; quinolone; recombinant endolysin; recombinant protein; tetracycline; unclassified drug; virus spike protein; antiinfective agent; endolysin; proteinase; recombinant protein, antibiotic resistance; antimicrobial activity; bacteriophage; drug delivery system; enzyme activity; enzyme engineering; enzyme structure; food safety; health care cost; host range; lactic acid bacterium; methicillin resistant Staphylococcus aureus; multidrug resistance; nanotechnology; nuclear magnetic resonance; penicillin resistance; phage therapy; physical chemistry; Review; Staphylococcus aureus; Staphylococcus infection; vancomycin resistant Staphylococcus aureus; drug delivery system; drug effect; research; Staphylococcus infection; trends, Anti-Bacterial Agents; Drug Delivery Systems; Endopeptidases; Methicillin-Resistant Staphylococcus aureus; Recombinant Proteins; Research; Staphylococcal Infections
Subjects: Immunology and Microbiology
Divisions: Faculty of Medicine > Basic Sciences > Department of Microbiology & Immunology
Depositing User: ART . editor
Date Deposited: 13 Apr 2019 09:44
Last Modified: 13 Apr 2019 09:44
URI: http://eprints.kaums.ac.ir/id/eprint/4068

Actions (login required)

View Item View Item